<abstract xmlns="http://www.w3.org/1999/xhtml">

Most gastric cancers (GC) are thought to be caused by <italic>Helicobacter pylori</italic> (<italic>H. pylori</italic>) infections. However, there is mounting evidence that GC patients with positive <italic>H. pylori</italic> status have improved prognoses. The <italic>H. pylori</italic>-induced cellular immune reaction may inhibit cancer. In this study, BALB/c mice were immunized using recombinant plasmids that encode the <italic>ureF</italic> gene of <italic>H. pylori</italic>. Purified functional splenic CD3+ T lymphocytes are used to study the anticancer effects <italic>in vitro</italic> and <italic>in vivo</italic>. The immunological state of GC patients with ongoing <italic>H. pylori</italic> infection is mimicked by the <italic>H. pylori</italic> DNA vaccines, which cause a change in the reaction from Th1 to Th2. Human GC cells grow more slowly when stimulated CD3+ T lymphocytes are used as adoptive infusions because they reduce GC xenograft development <italic>in vivo</italic>. The more excellent ratios of infiltrating CD8+/CD4+ T cells, the decreased invasion of regulatory FOXP3+ Treg lymphocytes, and the increased apoptosis brought on by Caspase9/Caspase-3 overexpression and Survivin downregulation may all contribute to the consequences. Our findings suggest that in people with advanced GC, <italic>H. pylori</italic> pIRES2-DsRed-Express-<italic>ureF</italic> DNA vaccines may have immunotherapeutic utility.
</abstract>

Most gastric cancers (GC) are thought to be caused by Helicobacter pylori (H. pylori) infections. However, there is mounting evidence that GC patients with positive H. pylori status have improved prognoses. The H. pylori-induced cellular immune reaction may inhibit cancer. In this study, BALB/c mice were immunized using recombinant plasmids that encode the ureF gene of H. pylori. Purified functional splenic CD3+ T lymphocytes are used to study the anticancer effects in vitro and in vivo. The immunological state of GC patients with ongoing H. pylori infection is mimicked by the H. pylori DNA vaccines, which cause a change in the reaction from Th1 to Th2. Human GC cells grow more slowly when stimulated CD3+ T lymphocytes are used as adoptive infusions because they reduce GC xenograft development in vivo. The more excellent ratios of infiltrating CD8+/CD4+ T cells, the decreased invasion of regulatory FOXP3+ Treg lymphocytes, and the increased apoptosis brought on by Caspase9/Caspase-3 overexpression and Survivin downregulation may all contribute to the consequences. Our findings suggest that in people with advanced GC, H. pylori pIRES2-DsRed-Express-ureF DNA vaccines may have immunotherapeutic utility.

Potential Gastric Cancer Immunotherapy: Stimulating the Immune System with <italic>Helicobacter pylori</italic> pIRES2-DsRed-Express-<italic>ureF</italic> DNA Vaccines

Biotechnology Research Center, Shahrekord Branch

Biotechnology Research Center, East Tehran Branch

Archivum Immunologiae et Therapiae Experimentalis

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Potential Gastric Cancer Immunotherapy: Stimulating the Immune System with  pIRES2-DsRed-Express- DNA Vaccines

Most gastric cancers (GC) are thought to be caused by Helicobacter pylori (H. pylori) infections. However, there is mounting evidence that GC patients with...

Potential Gastric Cancer Immunotherapy: Stimulating the Immune System with Helicobacter pylori pIRES2-DsRed-Express-ureF DNA Vaccines

Article Category: Original

Publié en ligne: 12 févr. 2024

Pages: -

Reçu: 26 févr. 2023

Accepté: 20 sept. 2023

DOI: https://doi.org/10.2478/aite-2024-0004

Mots clés
Gastric carcinoma, DNA vaccine, gene

© 2023 Mahsa Afkhamipour et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Potential Gastric Cancer Immunotherapy: Stimulating the Immune System with Helicobacter pylori pIRES2-DsRed-Express-ureF DNA Vaccines

Article Category: Original

Publié en ligne: 12 févr. 2024

Pages: -

Reçu: 26 févr. 2023

Accepté: 20 sept. 2023

DOI: https://doi.org/10.2478/aite-2024-0004

Mots clésGastric carcinoma, DNA vaccine, gene

© 2023 Mahsa Afkhamipour et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Mots clés
Gastric carcinoma, DNA vaccine, gene